Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer

A Phase I/II trial previously revealed variable anti-tumor efficacy of the PARP inhibitor niraparib in combination with the PD-1 inhibitor pembrolizumab in platinum-resistant ovarian cancer patients. Here, the authors perform an integrated genomic and immunomics analysis of tumor samples from the sa...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anniina Färkkilä, Doga C. Gulhan, Julia Casado, Connor A. Jacobson, Huy Nguyen, Bose Kochupurakkal, Zoltan Maliga, Clarence Yapp, Yu-An Chen, Denis Schapiro, Yinghui Zhou, Julie R. Graham, Bruce J. Dezube, Pamela Munster, Sandro Santagata, Elizabeth Garcia, Scott Rodig, Ana Lako, Dipanjan Chowdhury, Geoffrey I. Shapiro, Ursula A. Matulonis, Peter J. Park, Sampsa Hautaniemi, Peter K. Sorger, Elizabeth M. Swisher, Alan D. D’Andrea, Panagiotis A. Konstantinopoulos
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/bd4459e944254dc4845c521cfcab9cf4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bd4459e944254dc4845c521cfcab9cf4
record_format	dspace
spelling	oai:doaj.org-article:bd4459e944254dc4845c521cfcab9cf42021-12-02T14:41:23ZImmunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer10.1038/s41467-020-15315-82041-1723https://doaj.org/article/bd4459e944254dc4845c521cfcab9cf42020-03-01T00:00:00Zhttps://doi.org/10.1038/s41467-020-15315-8https://doaj.org/toc/2041-1723A Phase I/II trial previously revealed variable anti-tumor efficacy of the PARP inhibitor niraparib in combination with the PD-1 inhibitor pembrolizumab in platinum-resistant ovarian cancer patients. Here, the authors perform an integrated genomic and immunomics analysis of tumor samples from the same patients and find potential predictive biomarkers of response to such combination therapy.Anniina FärkkiläDoga C. GulhanJulia CasadoConnor A. JacobsonHuy NguyenBose KochupurakkalZoltan MaligaClarence YappYu-An ChenDenis SchapiroYinghui ZhouJulie R. GrahamBruce J. DezubePamela MunsterSandro SantagataElizabeth GarciaScott RodigAna LakoDipanjan ChowdhuryGeoffrey I. ShapiroUrsula A. MatulonisPeter J. ParkSampsa HautaniemiPeter K. SorgerElizabeth M. SwisherAlan D. D’AndreaPanagiotis A. KonstantinopoulosNature PortfolioarticleScienceQENNature Communications, Vol 11, Iss 1, Pp 1-13 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Anniina Färkkilä Doga C. Gulhan Julia Casado Connor A. Jacobson Huy Nguyen Bose Kochupurakkal Zoltan Maliga Clarence Yapp Yu-An Chen Denis Schapiro Yinghui Zhou Julie R. Graham Bruce J. Dezube Pamela Munster Sandro Santagata Elizabeth Garcia Scott Rodig Ana Lako Dipanjan Chowdhury Geoffrey I. Shapiro Ursula A. Matulonis Peter J. Park Sampsa Hautaniemi Peter K. Sorger Elizabeth M. Swisher Alan D. D’Andrea Panagiotis A. Konstantinopoulos Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
description	A Phase I/II trial previously revealed variable anti-tumor efficacy of the PARP inhibitor niraparib in combination with the PD-1 inhibitor pembrolizumab in platinum-resistant ovarian cancer patients. Here, the authors perform an integrated genomic and immunomics analysis of tumor samples from the same patients and find potential predictive biomarkers of response to such combination therapy.
format	article
author	Anniina Färkkilä Doga C. Gulhan Julia Casado Connor A. Jacobson Huy Nguyen Bose Kochupurakkal Zoltan Maliga Clarence Yapp Yu-An Chen Denis Schapiro Yinghui Zhou Julie R. Graham Bruce J. Dezube Pamela Munster Sandro Santagata Elizabeth Garcia Scott Rodig Ana Lako Dipanjan Chowdhury Geoffrey I. Shapiro Ursula A. Matulonis Peter J. Park Sampsa Hautaniemi Peter K. Sorger Elizabeth M. Swisher Alan D. D’Andrea Panagiotis A. Konstantinopoulos
author_facet	Anniina Färkkilä Doga C. Gulhan Julia Casado Connor A. Jacobson Huy Nguyen Bose Kochupurakkal Zoltan Maliga Clarence Yapp Yu-An Chen Denis Schapiro Yinghui Zhou Julie R. Graham Bruce J. Dezube Pamela Munster Sandro Santagata Elizabeth Garcia Scott Rodig Ana Lako Dipanjan Chowdhury Geoffrey I. Shapiro Ursula A. Matulonis Peter J. Park Sampsa Hautaniemi Peter K. Sorger Elizabeth M. Swisher Alan D. D’Andrea Panagiotis A. Konstantinopoulos
author_sort	Anniina Färkkilä
title	Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
title_short	Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
title_full	Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
title_fullStr	Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
title_full_unstemmed	Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
title_sort	immunogenomic profiling determines responses to combined parp and pd-1 inhibition in ovarian cancer
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/bd4459e944254dc4845c521cfcab9cf4
work_keys_str_mv	AT anniinafarkkila immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT dogacgulhan immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT juliacasado immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT connorajacobson immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT huynguyen immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT bosekochupurakkal immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT zoltanmaliga immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT clarenceyapp immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT yuanchen immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT denisschapiro immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT yinghuizhou immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT juliergraham immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT brucejdezube immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT pamelamunster immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT sandrosantagata immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT elizabethgarcia immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT scottrodig immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT analako immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT dipanjanchowdhury immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT geoffreyishapiro immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT ursulaamatulonis immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT peterjpark immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT sampsahautaniemi immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT peterksorger immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT elizabethmswisher immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT alanddandrea immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT panagiotisakonstantinopoulos immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer
_version_	1718389893839716352

Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer

Ejemplares similares